Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates
09:46am, Friday, 31'st Jan 2025
AbbVie (ABBV) came out with quarterly earnings of $2.16 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $2.79 per share a year ago.
AbbVie's newer immunology drugs are offsetting Humira's decline, sending stock up 4%
08:30am, Friday, 31'st Jan 2025
AbbVie's earnings topped estimates as it offered an upbeat view of 2025.
AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
07:40am, Friday, 31'st Jan 2025
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthriti
AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
07:36am, Friday, 31'st Jan 2025
Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
02:39pm, Thursday, 30'th Jan 2025
As AbbVie Inc. ABBV and Novartis AG NVS prepare to report their fourth-quarter earnings before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants.
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
09:00am, Tuesday, 28'th Jan 2025
Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
06:15am, Tuesday, 28'th Jan 2025
When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from
Why AbbVie Stock Popped While the Market Flopped on Monday
06:21pm, Monday, 27'th Jan 2025
Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (ABBV 3.88%) wasn't one of them. The storied pharmaceutical company saw its share price rise by almost 4%, on the b
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
01:13pm, Monday, 27'th Jan 2025
AbbVie Inc. ABBV will release its full-year and fourth-quarter 2024 financial results on Friday, Jan. 31.
AbbVie A Top Socially Responsible Dividend Stock With 3.9% Yield
09:11am, Monday, 27'th Jan 2025
AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.9% yield, as well as being r
3 More Cyclical Stocks to Buy for 2025
12:00pm, Sunday, 26'th Jan 2025
In last week's Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper miner Freeport–McMoRan Inc. ( FCX ) usually trade in a predetermined rang
AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
07:24am, Sunday, 26'th Jan 2025
AbbVie is expected to beat Q4 2024 revenue and EPS estimates, with strong performance from Skyrizi, Rinvoq, and neuroscience products offsetting Humira's decline. Management expects a return to "robus
5 Best CEFs This Month For Nearly 10% Yield (January 2025)
08:00am, Saturday, 25'th Jan 2025
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generall
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
11:06am, Friday, 24'th Jan 2025
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
09:21am, Friday, 24'th Jan 2025
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.
